CHCT
Community Healthcare Trust Incorporated
CHCT's fundamentals are mixed, but it looks cheap: trading at 20x earnings, about a third of its usual 64x. Analysts expect earnings growth.
CHCT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
CHCT's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for real estate companies like CHCT.
CHCT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 20x | $14.72 | — |
| Forward | 33x | $14.72 | — |
| Cheap | 41x | $30.67 | +108% |
| Fair | 62x | $46.06 | +213% |
| Expensive | 131x | $96.93 | +559% |
Historical ranges are pointers, not guarantees.
CHCT's PE is in its cheap range at 20x. On analysts' estimates for next year's earnings, today's price would be 33x.
CHCT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect CHCT's earnings to grow, with its revenue and profitability holding steady.
CHCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.45 | -39% |
| Q3 2026 | $0.74 | +$1.14 |
| Q2 2026 | $0.68 | +$1.07 |
| Q1 2026 | $0.12 | +$0.43 |
| Q4 2025 | $0.08 | +$0.31 |
| Q3 2025 | -$0.40 | -$0.30 |
| Q2 2025 | -$0.39 | -$0.36 |
| Q1 2025 | -$0.31 | -149% |
| Q4 2024 | -$0.23 | -215% |
CHCT has returned to profit: it earned $0.74 per share over the past year, after losing money the year before.
CHCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $32.4M | +4.4% |
| Q2 2026 | $31.2M | +7.4% |
| Q1 2026 | $31.5M | +4.8% |
| Q4 2025 | $30.9M | +5.6% |
| Q3 2025 | $31.1M | +4.9% |
| Q2 2025 | $29.1M | +5.7% |
| Q1 2025 | $30.1M | +2.5% |
| Q4 2024 | $29.3M | +0.6% |
CHCT's revenue has grown year over year for nine quarters in a row: $32M last quarter, up 4.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | 35% | -0.1 points |
| Q2 2022 | 35% | -2.6 points |
| Q1 2022 | 35% | -0.8 points |
| Q4 2021 | 38% | N/A |
| Q3 2021 | 35% | N/A |
| Q2 2021 | 37% | N/A |
| Q1 2021 | 35% | +0.1 points |
| Q1 2020 | 35% | N/A |
CHCT's operating margin was 35% last quarter, about level with the same quarter a year ago.
CHCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.1M | +20% |
| Q2 2026 | $13.3M | +39% |
| Q1 2026 | $8.8M | -9.8% |
| Q4 2025 | $9M | -15% |
| Q3 2025 | $7.6M | +15% |
| Q2 2025 | $9.6M | +0.3% |
| Q1 2025 | $9.7M | +29% |
| Q4 2024 | $10.5M | +55% |
CHCT's free cash flow was $40M over the past year, up 7.4% from the year before. Free cash flow isn't a meaningful measure for real estate companies like CHCT.
CHCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +54K shares |
| 1 year | +0.5% | +136K shares |
| 3 years | +6.1% | +1.6M shares |
| 5 years | +15% | +3.6M shares |
| Available history | +45% | +8.4M shares |
CHCT has 27M diluted shares, up 0.5% from a year ago.
CHCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | 4.7x | High |
| Q2 2022 | 4.5x | High |
| Q1 2022 | 4.2x | High |
| Q4 2021 | 4.2x | High |
| Q1 2020 | 5.0x | High |
| Q4 2019 | 5.6x | High |
CHCT's net debt is about 4.7 years of its operating earnings (EBITDA), down from 5.0 years a year ago. Net leverage isn't a meaningful measure for real estate companies like CHCT.
CHCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 36.1 | Neutral |
CHCT's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
CHCT PE vs Real Estate Sector
| Metric | CHCT | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 24x | 17% below |
| PE % | 1 | 23 | 22 pts below |
CHCT is trading at 20x earnings, a 17% discount to the Real Estate sector's median of 24x.
CHCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.8 | 6.7% above |
| 20 week MA | $15.4 | 4.2% below |
| 50 week MA | $16.3 | 9.6% below |
| 100 week MA | $16.5 | 11% below |
| 200 week MA | $22.2 | 34% below |
CHCT has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 34% below its 200-week average.
CHCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $42.2 | $46.9 | +11% |
| 2021 | $46.9 | $45.4 | -3.1% |
| 2022 | $45.4 | $35.7 | -21% |
| 2023 | $35.7 | $26.6 | -25% |
| 2024 | $26.6 | $18.4 | -31% |
| 2025 | $18.4 | $16.0 | -13% |
| 2026 YTD | $16.0 | $14.7 | -7.7% |
CHCT has finished five years in a row lower, and it's down 7.7% so far in 2026.